Is Trident Lifeline the Best Stock in Its Sector? A Look at the Numbers

Is Trident Lifeline the best stock in its sector? The stock trades on the BSE at Rs 402 as of 21 October 2026, within its 52-week range of Rs 229.95 to Rs 425.00. The sections below cover the business, the key ratios, a peer comparison and a closer look at valuation.

Also read – Is Abbott India the Best Stock in Its Sector? A Look at the Numbers

Click Here – Get Free Investment Predictions

About Trident Lifeline

Trident Lifeline Ltd is a Surat based company that company information says was incorporated in 2014 and that manufactures and sells pharmaceutical products. It is described as having started as an export oriented formulations business that relied on third party and loan licence manufacturing, and it is now said to be evolving into a vertically integrated healthcare manufacturing platform through its own and subsidiary facilities. At a market capitalisation of Rs 482 Cr, it is tracked as part of the Pharmaceutical Formulations sector on Univest.

Is Trident Lifeline the Best Stock in Its Sector?

Trident Lifeline makes its case as the best stock in its sector primarily on valuation relative to its Industry P/E, backed by its return on equity. Trident Lifeline's 22.30x P/E is below the 35.97x Industry P/E, Marksans Pharma at 27.32x and Ajanta Pharma at 36.31x, while its 18.97% ROE is lower than Ajanta Pharma at 23.33%, though higher than Marksans Pharma at 13.82%, and its debt to equity ratio of 0.73 is above Marksans Pharma at 0.11 and Ajanta Pharma at 0.06.

Metric	Trident Lifeline
CMP (BSE)	Rs 402.00
52-Week High / Low	Rs 425.00 / Rs 229.95
Market Cap	Rs 482 Cr
P/E (TTM) vs Industry P/E	22.30x vs 35.97x
P/B	4.92
ROE	18.97%
EPS (TTM)	Rs 18.03
Dividend Yield	0.00%
Debt to Equity	0.73

Compare Trident Lifeline Against Other Pharmaceutical Formulations Sector Stocks

How Trident Lifeline Compares Against Its Pharmaceutical Formulations Sector Peers

The table below sets Trident Lifeline against 2 other Pharmaceutical Formulations sector names, using the same live data source for every company. A peer average row is included for P/E, ROE and debt to equity, calculated across the 2 peer companies.

Company	Market Cap (Rs Cr)	P/E	ROE	Debt to Equity
Trident Lifeline	482	22.30	18.97%	0.73
Marksans Pharma	14,236	27.32	13.82%	0.11
Ajanta Pharma	41,211	36.31	23.33%	0.06
Peer average (2 companies)	-	31.82	18.57%	0.08

Measured against the peer averages, Trident Lifeline's P/E is 30 percent below the 31.82x average, and its ROE is 0.39 percentage points above the 18.57% average. An average of just two companies is a rough guide, so treat the gap as a pointer for further research and not as a verdict.

What Makes Trident Lifeline Worth Watching in Pharmaceutical Formulations

• Scale: At Rs 482 Cr, its market capitalisation is smaller than Marksans Pharma (Rs 14,236 Cr) and Ajanta Pharma (Rs 41,211 Cr), which is a useful reminder that the peers differ in size as well as in valuation.
• Sector drivers: The shift from outsourced manufacturing towards its own and subsidiary facilities is the main thing to watch, since it can change both capacity and the margin the company keeps on each product.
• Key risk: A move from contract manufacturing to owned plants usually needs fresh capital, and its borrowing is heavier than that of both peers shown, so execution and funding costs matter. Thin trading in a small cap stock can also make prices swing sharply.

Trident Lifeline Valuation: Is It Justified?

At a P/B ratio of 4.92, the market pays about Rs 4.92 for every rupee of book value, and the EPS (TTM) of Rs 18.03 is the earnings base behind the P/E. The stock trades about 5 percent below its 52-week high and about 75 percent above its 52-week low. The company does not currently show a dividend yield, so returns for shareholders depend mainly on the share price. As with any single stock, investors should weigh these figures against their own valuation discipline and risk appetite rather than the sector label alone.

Also read – Is Oracle Financial Services Software the Best Stock in Its Sector? A Look at the Numbers

Download the Univest iOS App or Univest Android App to track Trident Lifeline and other Pharmaceutical Formulations sector stocks.

How to Track Trident Lifeline Before You Invest

Before deciding whether Trident Lifeline deserves its label as the best stock in its sector for your own portfolio, compare it directly against Pharmaceutical Formulations sector peers using the steps below.

1. Open the Univest Screener and search for Trident Lifeline to view live price, valuation ratios, and peer comparisons within the Pharmaceutical Formulations sector.
2. Compare its P/E, P/B, and ROE against other Pharmaceutical Formulations sector stocks before deciding if the current valuation fits your strategy.
3. Set a price alert around key support and resistance zones using the Univest app so you are notified of meaningful moves.
4. Open a broking account on Univest if you decide to add the stock, and size the position based on your own risk appetite and portfolio allocation.

Conclusion

Trident Lifeline gives investors a clear set of numbers to work with, from returns and valuation to leverage and peer standing. Whether it earns the label of best stock in Pharmaceutical Formulations depends on how much weight you give each of them and on how the business executes from here. Because the stock trades below its sector benchmark, the open question is whether earnings growth will close that gap or whether the discount is deserved. As with any individual stock decision, this analysis is educational and investors should do their own research or consult a SEBI-registered advisor before investing.

Is Trident Lifeline the best stock in its sector?

Ans. There is no single definitive answer, because the best stock in a sector depends on whether an investor is prioritising returns, valuation or balance sheet strength. Trident Lifeline has an 18.97% ROE and trades at 22.30x P/E against a 35.97x Industry P/E. Against the 2 peers compared in this article, its ROE is above the 18.57% peer average and its P/E is below the 31.82x peer average. Its debt to equity ratio of 0.73 is above the 0.08 peer average, which matters because borrowing can inflate returns and add risk when business conditions weaken. These figures are best read together rather than in isolation, and they work as a starting point for your own research and not as a verdict.

What is the current share price of Trident Lifeline?

Ans. Trident Lifeline was trading at Rs 402.00 on the BSE as of 21 October 2026, and its 52-week range runs from Rs 229.95 to Rs 425.00. That leaves the share price 5 percent short of the 52-week high and 75 percent clear of the 52-week low. Its market capitalisation is Rs 482 Cr and its EPS (TTM) is Rs 18.03, which is the earnings figure behind the 22.30x P/E. Share prices change through the trading day, so check the live quote on Univest before acting on any number here.

What sector does Trident Lifeline belong to?

Ans. Trident Lifeline is classified under the Pharmaceutical Formulations sector on Univest, and that group of listed companies is the reference point for the 35.97x Industry P/E used in this article. The 2 named peers compared here are Marksans Pharma and Ajanta Pharma, chosen as comparable listed names so that the P/E, ROE and debt figures come from the same live data source. Investors who want a wider view can compare more Pharmaceutical Formulations sector stocks on the Univest Screener, since no two companies in a sector have exactly the same business mix.

How does Trident Lifeline compare to its sector peers on P/E?

Ans. Trident Lifeline's P/E of 22.30x is below the 31.82x average of the 2 named peers, with Marksans Pharma at 27.32x and Ajanta Pharma at 36.31x. It also sits below the 35.97x Industry P/E, which is the benchmark for the wider Pharmaceutical Formulations sector. A P/E that is below a peer average can reflect a valuation discount or premium, but it can also reflect different growth or return expectations, so it should be read alongside ROE and debt. Its P/B ratio of 4.92 gives one more view of how the market values its book value.

What is Trident Lifeline's return on equity?

Ans. Trident Lifeline reported a return on equity of 18.97%, which is above the 18.57% average of its named peers, with Marksans Pharma at 13.82% and Ajanta Pharma at 23.33%. ROE shows how much profit a company generates on every rupee of shareholders' equity, so a higher figure generally points to more efficient use of capital. ROE is easier to trust when leverage is modest, and here the debt to equity ratio is 0.73 against a peer average of 0.08. It is worth checking whether the ROE has been stable over several years rather than relying on a single reading.

Should I invest in Trident Lifeline based on its sector position?

Ans. Sector position is only one input into an investment decision. Trident Lifeline has an 18.97% ROE and a 22.30x P/E, which make it worth researching further, and its dividend yield is 0.00%. You should also weigh its business outlook, earnings consistency, debt levels, your investment horizon and your own risk appetite before buying. Spreading money across several stocks and sectors reduces concentration risk, and this article is educational content, not investment advice. For personalised guidance, consult a SEBI-registered advisor.